Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells

Cancer Research

Volumn 59, Issue 19, 1999, Pages 4973-4983

  Bruening, Wendy ^a   Prowse, Amanda H ^a   Schultz, David C ^a,b   Holgado Madruga, Marina ^c   Wong, Albert ^c   Godwin, Andrew K ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b WISTAR INSTITUTE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1;

ARTICLE; BREAST CANCER; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR SUPPRESSOR GENE;

AMINO ACID SUBSTITUTION; CELL CYCLE; CELL DIVISION; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; KINETICS; LOSS OF HETEROZYGOSITY; OVARIAN NEOPLASMS; PLASMIDS; POINT MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEINS; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; VARIATION (GENETICS);

EID: 0033214036     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Thai, T. H., Du, F., Tsan, J. T., Jin, Y., Phung, A., Spillman, M. A., Massa, H. F., Muller, C. Y., Ashfaq, R., Mathis, J. M., Miller, D. S., Trask, B. J., Baer, R., and Bowcock, A. M. Mutations in the BRCA 1-associated RING domain (BARD1) gene in primary breast, ovarian, and uterine cancers. Hum. Mol. Genet., 7: 195-202, 1998.
2. Carney, M. E., Maxwell, G. L., Lancaster, J. M., Gumbs, C., Marks, J., Berchuck, A., and Futreal, P. A. Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers. J. Soc. Gynecol. Invest., 5: 281-285, 1998.
3. Gayther, S. A., Barski, P., Batley, S. J., Li, L., de Foy, K. A., Cohen, S. N., Ponder, B. A., and Caldas, C. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Oncogene, 15: 2119-2126, 1997.
4. Obata, K., Morland, S. J., Watson, R. H., Hitchcock, A., Chenevix-Trench, G., Thomas, E. J., and Campbell, I. G. Frequent PTEN/MMAC mutations in endometroid but not serous or mucinous epithelial ovarian tumors. Cancer Res., 58: 2095-2097, 1998.
5. Maxwell, G. L., Risinger, J. I., Tong, B., Shaw, H., Barrett, J. C., Berchuck, A., and Futreal, P. A. Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers. Gynecol. Oncol., 70: 13-16, 1998.
6. Yokomizo, A., Tindall, D. J., Hartmann, L., Jenkins, R. B., Smith, D. I., and Liu, W. Mutation analysis of the putative tumor suppressor PTEN/MMAC1 in human ovarian cancer. Int. J. Oncol., 13: 101-105, 1998.
7. Schutte, M., Hruban, R. H., Hedrick, L., Cho, K. R., Nadasdy, G. M., Weinstein, C. L., Bova, G. S., Isaacs, W. B., Cairns, P., Nawroz, H., Sidransky, D., Casero, R. A. J., Meltzer, P. S., Hahn, S. A., and Kern, S. E. DPC4 gene in various tumor types. Cancer Res., 56: 2527-2530, 1996.
8. Yinhua, Y., Fengji, X., Peng, H., Fang, X., Zhao, S., Li, Y., Cuevas, B., Kuo, W. L., Gray, J. W., Siciliano, M., Mills, G. B., and Bast, R. C. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc. Natl. Acad. Sci. USA, 96: 214-219, 1999.
9. Mok, S. C., Chan, W. Y., Wong, K. K., Cheung, K. K., Lau, C. C., Ng, S. W., Baldini, A., Colitti, C. V., Rock, C. O., and Berkowitz, R. S. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene, 16: 2381-2387, 1998.
10. Abdollahi, A., Godwin, A., Miller, P., Getts, L., Schultz, D., Taguchi, T., Testa, J., and Hamilton, T. Identification of a gene containing zinc-finger motifs based on lost expression in malignantly transformed rat ovarian surface epithelial cells. Cancer Res., 57: 2029-2034, 1997.
11. Abdollahi, A., Roberts, D., Godwin, A., Schultz, D., Sonoda, G., Testa, J., and Hamilton, T. Identification of a zinc-finger gene at 6q25: a chromosomal region implicated in the development of many solid tumors. Oncogene, 14: 1973-1979, 1997.
12. Godwin, A., Schultz, D., Hamilton, T., and Knudson, A. Oncogenes and tumor suppressor genes. In: W. Hoskins, C. Perez, and R. Young (eds.). Principles and Practice of Gynecological Oncology, pp. 107-148. Philadelphia: J. B. Lippincott Co., 1997.
13. Lynch, H. T., Casey, M. J., Lynch, J., White, T. E. K., and Godwin, A. K. Genetics and ovarian carcinoma. Semin. Oncol., 25: 265-280, 1998.
14. Phillips, N., Ziegler, M. R., SaHa, B., and Xynos, F. Allelic loss on chromosome 17 in human ovarian cancer. Int. J. Cancer, 54: 85-91, 1993.
15. Phillips, N., Ziegler, M., Radford, D., Fair, K., Steinbrueck, T., Xynos, F., and Donis-Keller, H. Allelic deletion on chromosome 17p13.3 in early ovarian cancer. Cancer Res., 56: 606-611, 1996.
16. Phelan, C., Borg, A., Cuny, M., Crichton, D., Baldersson, T., Andersen, T., Caligo, M., Lidereau, R., Lindblom, A., Seitz, S., Kelsell, D., Hamann, U., Rio, P., Thorlacius, S., Papp, J., Olah, E., Ponder, B., Bignon, Y-J., Scherneck, S., Barkardottir, R., Borresen-Dale, A-L., Eyfjord, J., Theillet, C., Thompson, A., Devilee, P., and Larsson, C. Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subrogions associated with family history and clinical parameters. Cancer Res., 58: 1004-1012, 1998.
17. Mackay, J., Elder, P., Steel, C., Forrest, A., and Evans, H. Allele loss on short arm of chromosome 17 in breast cancers. Lancet, 17: 1384-1385, 1988.
18. Devilee, P., Pearson, P., and Cornelisse, C. Allele losses in breast cancer. Lancet, 1: 154, 1989.
19. Singh, S., Simon, M., Meybohm, I., Jantke, I., Jonat, W., Maass, H., and Goedde, H. Human breast cancer: frequent p53 allele loss and protein overexpression. Hum. Genet., 90: 635-640, 1993.
20. Cornelis, R., van Vliet, M., Vos, C., Cleton-Jansen, A-M., van de Vijver, M., Peterse, J., Khan, P., Borresen, A-L., Cornelisse, C., and Devilee, P. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res., 54: 4200-4206, 1994.
21. Harada, Y., Katagiri, T., Ito, I., Akiyama, F., Sakamoto, G., Kasumi, F., Nakamura, Y., and Emi, M. Genetic studies of 457 breast cancers. Cancer (Phila.), 74: 2281-2286, 1994.
22. Stack, M., Jones, D., White, G., Liscia, D., Venesio, T., Casey, G., Crichton, D., Varley, J., Mitchell, E., Heighway, J., and Santibanez-Koref, M. Detailed mapping and loss of heterozygosity analysis suggests a suppressor locus involved in sporadic breast cancer within a distal region of chromosome band 17p13.3. Hum. Mol. Genet., 4: 2047-2055, 1995.
23. Thompson, A., Crichton, D., Elton, R., Clay, M., Chetty, U., and Steel, C. Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium-term follow-up. Br. J. Cancer, 77: 797-800, 1998.
24. Ito, I., Yoshimoto, M., Iwase, T., Watanabe, S., Katagiri, T., Harada, Y., Kasumi, F., Yasuda, S., Mitomi, T., Emi, M., and Nakamura, Y. Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer. Br. J. Cancer, 71: 438-441, 1995.
25. Nagai, M. A., Medeiros, A., Brentani, M. M., Marques, L. A., Mazoyer, S., and Mulligan, L. M. Five distinct deleted regions on chromosome 17 defining different subsets of human primary breast tumor. Oncogene, 52: 448-453, 1995.
26. Marchetti, A., Buttitta, F., Merlo, G., Diella, F., Pellegrini, S., Pepe, S., Macchiarini, P., Chella, A., Angeletti, A., Callahan, R., Bistocchi, M., and Squartini, F. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res., 53: 2846-2851, 1993.
27. Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A. F., and Minna, J. D. p53: a frequent target for genetic abnormalities in lung cancer. Science (Washington DC), 246: 491-494, 1989.
28. Konishi, H., Takahashi, T., Kozaki, K., Yatabe, Y., Mitsudomi, T., Fujii, Y., Sugiura, T., Matsuda, H., Takahashi, T., and Takahashi, T. Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers. Oncogene, 17: 2095-2100, 1998.
29. Baker, S., Fearon, E., Nigro, J., Hamilton, S., Preisinger, A., Jessup, J., vanTuinen, P., Ledbetter, D., Barker, D., Nakamura, Y., White, R., and Vogelstein, B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (Washington DC), 244: 217-221, 1989.
30. Haataja, L., Raffel, C., Ledbetter, D., Tanigami, A., Petersen, D., Heisterkamp, N., and Groffen, J. Deletion within the D17S34 locus in a primitive neuroectodermal tumor. Cancer Res., 57: 32-34, 1997.
31. Biegel, J., Rorke, L., Janss, A., Sutton, L., and Parmiter, A. Isochromosome 17q demonstrated by interphase fluorescence in situ hybridization in primitive neuroectodermal tumors of the central nervous system. Genes Chromosomes Cancer, 14: 85-96, 1995.
32. Biegel, J., Burk, C., Barr, F., and Emanuel, B. Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors. Cancer Res., 52: 3391-3395, 1992.
33. Park, S-Y., Kang, Y-S., Kim, B-G., Lee, S-H., Lee, E-D., Lee, K-H., Park, K-B., and Lee, J-H. Loss of heterozygosity on the short arm of chromosome 17 in uterine cervical carcinomas. Cancer Genet. Cytogenet., 79: 74-78, 1995.
34. Kersemaekers, A-M., Kenter, G., Hermans, J., Fleuren, G., and van de Vijver, M. Allelic loss and prognosis in carcinoma of the uterine cervix. Int. J. Cancer, 79: 411-417, 1998.
35. Kersemaekers, A., Hermans, J., Fleuren, G., and van de Vijver, M. Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinomas of the uterine cervix. Br. J. Cancer, 77: 192-200, 1998.
36. Atkin, N. B., and Baker, M. C. Chromosome 17p loss in carcinoma of the cervix uteri. Cancer Genet. Cytogenet., 37: 229-233, 1989.
37. Saylors, R., Sidransky, D., Friedman, H. S., Bigner, S. H., Bigner, D. D., Vogelstein, B., and Brodeur, G. M. Infrequent p53 gene mutations in medulloblastomas. Cancer Res., 51: 4721-4723, 1991.
38. McDonald, J., Daneshvar, L., Willert, J., Matsumara, K., Waldman, F., and Cogen, P. Physical mapping of chromosome 17p13.3 in the region of a putative tumor suppressor gene important in medulloblastoma. Genomics, 23: 229-232, 1994.
39. Scheurlen, W., Krauss, J., and Kuhl, J. No preferential loss of one parental allele of chromosome 17p13.3 in childhood medulloblastoma. Int. J. Cancer, 63: 372-374, 1995.
40. Cogen, P., Daneshvar, L., Metzger, A., Duyk, G., Edwards, M., and Sheffield, V. Involvement of multiple chromosome 17p loci in medulloblastoma tumorigenesis. Am. J. Hum. Genet., 50: 584-589, 1992.
41. Chattopadhyay, P., Rathore, A., Mathur, M., Sarkar, C., Mahapatra, S., and Sinha, S. Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours. Oncogene, 15: 871-875, 1997.
42. Saxena, A., Clark, W., Robertson, J., Ikejiri, B., Oldfield, E., and Ali, I. Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas. Cancer Res., 52: 6716-6721, 1992.
43. Grebe, S., McIver, B., Hay, I., Wu, P., Maciel, L., Drabkin, H., Goellner, J., Grant, C., Jenkins, R., and Eberhardt, N. Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular hybrid carcinoma. Clin. Endocrinol. Melab., 82: 3684-3691, 1997.
44. Tomlinson, I., Gammack, A., Stickland, J., Mann, G., MacKie, R., Kefford, R., and McGee, J. D. Loss of heterozygosity in malignant melanoma at loci on chromosomes 11 and 17 implicated in the pathogenesis of other cancers. Genes Chromosomes Cancer, 7: 169-172, 1993.
45. Nishida, N., Fukuda, Y., Kokuryu, H., Toguchida, J., Yandell, D., Ikenega, M., Imura, H., and Ishizaki, K. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res., 53: 368-372, 1993.
46. Sankar, M., Tanaka, K., Kumaravel, T., Arif, M., Shintani, T., Yagi, S., Kyo, T., Dohy, H., and Kamada, N. Identification of a commonly deleted region at 17p13.3 in leukemia and lymphoma associated with 17p abnormality. Leukemia (Baltimore), 12: 510-516, 1998.
47. Schultz, D. C., Vanderveer, L., Berman, D. B., Hamilton, T. C., Wong, A. J., and Godwin, A. K. Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res., 56: 1997-2002, 1996.
48. Phillips, N. J., Ziegler, M. R., and Deaven, L. L. A cDNA from the ovarian cancer critical region of deletion on chromosome 17p13.3. Cancer Lett., 102: 85-90, 1996.
49. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990.
50. Bookstein, R., Shew, J. Y., Chen, P. L., Scully, P., and Lee, W. H. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science (Washington DC), 247: 712-715, 1990.
51. Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., and Oren, M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA, 86: 8763-8767, 1989.
52. Finlay, C. A., Hinds, P. W., and Levine, A. The p53 proto-oncogene can act as a suppressor of transformation. Cell, 57: 1083-1093, 1989.
53. Holt, J. T., Thompson, M. E., Szabo, C., Robinson-Benion, C., Arteaga, C. L., King, M. C., and Jensen, R. A. Growth retardation and tumour inhibition by BRCA1. Nat. Genet., 12: 298-302, 1996.
54. Huang, H. J. S., Yee, J. K., Shew, J. Y., Chen, P. L., Bookstein, R., Friedmann, T., Lee, E. Y. H. P., and Lee, W. H. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science (Washington DC), 242: 1563-1566, 1988.
55. Ligget, W. H. J., Dewell, D. A., Rocco, J., Ahrendt, S. A., Koch, W., and Sidransky, D. p16 and p16β are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res., 56: 4119-4123, 1996.
56. Mattheakis, L. C., Sor, F., and Collier, R. J. Diphthamide synthesis in Saccharomyces cerevisiae: structure of the DPH2 gene. Gene, 132: 149-154, 1993.
57. Schultz, D. C., Balasara, B. R., Testa, J. R., and Godwin, A. K. Cloning and localization of the human diphthamide biosynthesis protein-2 gene, hDPH2. Genomics, 52: 186-191, 1998.
58. Choi, Y. H., Lee, S. J., Nguyen, P. M., Jang, J. S., Lee, J., Wu, M. L., Takano, E., Maki, M., Henkart, P. A., and Trepel, J. B. Regulation of cyclin D1 by calpain protease. J. Biol. Chem., 272: 28479-28484, 1997.
59. Sherr, C. J. D-type cyclins. Trends Biochem. Sci., 20: 187-190, 1995.
60. Motokura, T., and Arnold, A. Cyclin D and oncogenesis. Curr. Opin. Genet. Dev., 3: 5-10, 1993.
61. Masciullo, V., Scambia, G., Marone, M., Giannitelli, C., Ferrandina, G., Bellacosa, A., Benedetti, P., and Mancuso, S. Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas. Int. J. Cancer, 74: 390-395, 1997.
62. Welker, M., Lukas, J., Strauss, M., and Bartek, J. Enhanced protein stability: a novel mechanism of D-type cyclin over-abundance identified in human sarcoma cells. Oncogene, 13: 419-425, 1996.
63. Knudson, A. G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA, 68: 820-823, 1971.
64. Fera, M. L., Randel, E., Gurley, K. E., Roberts, J. M., and Kemp, C. J. The murine gene p27 Kipl is haplo-insufficient for tumour suppression. Nature (Lond.), 396: 177-180, 1998.
65. Di Cristofano, A., Pesce, B., Cordon-Cardo, C., Pandolfi, P. P. Pten is essential for embryonic development and tumour suppression. Nat. Genet., 19: 348-355, 1998.
66. Yang, R. M., Naitoh, J., Murphy, M., Wang, H. J., Phillipson, J., deKernion, J. B., Loda, M., and Reiter, R. E. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol., 159: 941-945, 1988.
67. Yasui, W., Kudo, Y., Semba, S., Yokozaki, H., and Tahara, E. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn. J. Cancer Res., 88: 625-629, 1997.
68. Esposito, V., Baldi, A., De Luca, A., Groger, A. M., Loda, M., Giordano, G. G., Caputi, M., Baldi, F., Pagano, M., and Giordano, A. Prognostic role of the cyclindependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res., 57: 3381-3385, 1997.
69. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M., and Pagano, M. Increased proteasome-dependent degradation of the cyclindependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231-234, 1997.
70. Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., and Roberts, J. M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.
71. Spirin, K. S., Simpson, J. F., Takeuchi, S., Kawamata, N., Miller, C. W., and Koeffler, H. P. p27/Kip1 mutation found in breast cancer. Cancer Res., 56: 2400-2404, 1996.
72. Kawamata, N., Morosetti, R., Miller, C. W., Park, D., Spirin, K. S., Nakamaki, T., Takeuchi, S., Hatta, Y., Simpson, J., Wilcyznski, S., et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res., 55: 2266-2269, 1995.
73. Morosetti, R., Kawamata, N., Gombart, A. F., Miller, C. W., Hatta, Y., Hirama, T., Said, J. W., Tomonaga, M., and Koeffler, H. P. Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood, 86: 1924-1930, 1995.
74. Pietenpol, J. A., Bohlander, S. K., Sato, Y., Papadopoulos, N., Liu, B., Friedman, C., Trask, B. J., Roberts, J. M., Kinzler, K. W., Rowley, J. D., and Vogelstein, B. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res., 55: 1206-1210, 1995.
75. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H., and Parsons, R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (Washington DC), 275: 1943-1947, 1997.
76. Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D. H., and Tavtigian, S. V. Identification of a candidate tumour suppressor gene, MMACI, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet., 15; 356-362, 1997.
77. Guldberg, P., thor Straten, P., Birck, A., Ahrenkiel, V., Kirkin, A. F., and Zeuthen, J. Disruption of the MMACIIPTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res., 57: 3660-3663, 1997.
78. Liaw, D., Marsh, D. J., Li, J., Dahia, P. L., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacocke, M., Eng, C., and Parsons, R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet., 16: 64-67, 1997.
79. Marsh, D. J., Coulon, V., Lunetta, K. L., Rocca-Serra, P., Dahia, P. L. M., Zheng, Z., Liaw, D., Caron, S., Duboue, B., Lin, A. Y., Richardson, A-L., Bonnetblanc, J-M., Bressieux, J-M., Cabarrot-Moreau, A., Chompret, A., Demange, L., Eeles, R. A., Yahanda, A. M., Fearon, E. R., Fricker, J-P., Gorlin, R. J., Hodgson, S. V., Huson, S., Lacombe, D., LePrat, F., Odent, S., Toulouse, C., Olopade, O. I., Sobol, H., Tishler, S., Woods, C. G., Robinson, B. G., Weber, H. C., Parsons, R., Peacocke, M., Longy, M., and Eng, C. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet., 7: 507-515, 1998.
80. Nelen, M. R., van Staveren, W. C., Peeters, E. A., Hassel, M. B., Gorlin, R. J., Hamm, H., Lindboe, C. F., Fryns, J. P., Sijmons, R. H., Woods, D. G., Mariman, E. C., Padberg, G. W., and Kremer, H. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum. Mol. Genet., 6: 1383-1387, 1997.